AI assistant
Bio Green Med Solution, Inc. — Director's Dealing 2013
Jan 30, 2013
35092_dirs_2013-01-29_fc63795c-f056-4fe4-aea3-af44671adce4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2013-01-25
Reporting Person: Rombotis Spiro George (Director, President & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2013-01-25 | Common Stock, $0.001 par value per share | A | 10791 | — | Acquired | 168292 | Direct |
| 2013-01-25 | Common Stock, $0.001 par value per share | A | 20000 | — | Acquired | 157501 | Direct |
Footnotes
F1: These securities were issued as part of the Issuer's annual equity compensation to executive officers under the Issuer's Amended and Restated 2006 Equity Incentive Plan.
F2: Of the shares of common stock reported, 142 shares are held indirectly by Mr. Rombotis through his IRA account and 30,714 shares are represented by unvested restricted stock units.
F3: Of the shares of common stock reported, 20,000 are represented by restricted stock units which will vest upon the fulfillment of certain clinical and financial conditions and terminate if they have not vested by December 31, 2014.